Healthcare Equipment and Supplies
Company Overview of Ventana Medical Systems, Inc.
Ventana Medical Systems Inc. develops, manufactures, and markets instrument-reagent systems that automate slide staining. Its clinical systems are used in anatomical pathology labs in analyzing human tissue to assist in diagnosing and treating cancer and infectious diseases. Ventana’s drug-discovery systems are used by pharmaceutical and biotech companies to increase the discovery of new drug targets and to evaluate the safety of new compounds. It also markets consumable products, including reagents and other accessories, and serves hospital-based anatomical pathology labs, independent reference labs, government labs, medical research centers, and resellers serving these entities. Ventana Me...
1910 East Innovation Park Drive
Tucson, AZ 85755
Founded in 1985
Key Executives for Ventana Medical Systems, Inc.
Chief Executive Officer and Director
Founder, Chairman Emeritus, Chief Scientific Officer and Chief Medical Officer
Chief Financial Officer and Senior Vice President
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2014.
Ventana Medical Systems, Inc. Key Developments
Ventana Medical Systems, Inc. Enters into Master Collaboration Agreement with Astellas Pharma Inc
Apr 14 15
Ventana Medical Systems, Inc. announced it has entered into master collaboration agreement with Astellas Pharma Inc. to develop novel automated tissue diagnostics in support of therapeutic compounds in development. Initial projects related to this agreement will support early-stage clinical trials for the Astellas therapeutic compound ASP5878, a novel small-molecule fibroblast growth factor receptor (FGFR) inhibitor which has been shown to block the kinase activities of FGFR1, FGFR2, FGFR3 and FGFR4. Ventana will develop, in parallel, an immunohistochemistry (IHC) test identifying FGF19 in certain solid tumors.
Ventana Medical Systems, Inc. Announces Collaboration to Develop Companion Diagnostics for ImmunoGen, Inc.'s Targeted Anticancer Agents
Oct 28 14
Ventana Medical Systems, Inc. announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancers (NSCLC). The goal of the collaboration is to leverage Ventana's expertise in companion diagnostic development, from prototyping through regulatory approval and commercialization, to identify specific patient populations for ImmunoGen's bio-target directed therapies. This pharma collaboration is one of dozens currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tools that help identify those individuals who are most likely to benefit from specific treatments. In addition to ImmunoGen, Ventana has announced collaborations with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more.
Ventana Medical Systems, Inc. Enters into Agreement with Quintiles, Inc. to Offer College of American Pathology-Standard Companion Diagnostic Testing Services in China
Aug 5 14
Ventana Medical Systems, Inc. announced a new agreement with Quintiles, Inc. to offer College of American Pathology (CAP)-standard companion diagnostic testing services in China for pharmaceutical and biotech companies conducting early phase clinical trials. Early phase clinical trial testing according to the rigorous CAP standards set by Ventana is available now.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|